Insulin resistance and atherosclerosis

Jugoslovenska Medicinska Biohemija

Volumn 25, Issue 4, 2006, Pages 343-348

  Micić, Dragan D ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Atherosclerosis; Endothelial dysfunction; Insulin resistance

Indexed keywords

ANTICOAGULANT AGENT; FATTY ACID; GLUCOSE; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PROCOAGULANT; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE ASSOCIATION; DOWNSTREAM PROCESSING; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; SKELETAL MUSCLE; VASOCONSTRICTION; VASODILATATION; WAIST CIRCUMFERENCE;

EID: 33845353792     PISSN: 03543447     EISSN: None     Source Type: Journal    
DOI: 10.2298/JMB0604343M     Document Type: Conference Paper

References (33)

1. Nigro J, Osman N, Dart AM, Little PJ. Insulin Resistance and Atherosclerosis. Endocrine Reviews 2006; 27 (3): 242-59.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
3. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995: 15: 551-61.
4. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-5.
5. Reaven G. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
6. Kurtz TW. New Treatment Strategies for Patients with Hypertension and Insulin Resistance. Am Med 2006; 119: 24S-30S.
7. Kahn R, Buse J, Ferannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-304.
8. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006; 116: 1813-22.
9. Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni's »De sedibus et causis morborum per anatomem indagata«. Int J Obes Relat Metab Disord 2003; 27: 534-5.
10. Studien KE. Hypertonie-Hyperglykamie-Hyperurikamiessyndrome. Zentralblatt für innere Medizin 1923 (44).
11. Himsworth H. The mechanism of diabetes mellitus. III. Human diabetes mellitus. Lancet 1939; 2: 171-5.
12. Vague J. La differenciation sexuelle, facteur determinant des formes de l'obesite. Presse Med 1947: 30: 339-40.
13. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipemia, diabete mellito e obesita di media grado. Acta Diabetol Latina 1967; 4: 36-41.
14. Zimmet P, Alberti A. The IDF definition: why we need a global consensus. Diabetes Voice 2006; 51: 11-4.
15. Sowers JR. The Journal of the CardioMetabolic Syndrome: Why It Is Needed. Journal of the CardioMetabolic Syndrome 2006; 1: 5.
16. Reaven GM. The Metabolic Syndrome: Requiescat in Pace. Clinical Chemistry 2005; 51: 931-8.
17. Reaven GM, The insulin resistance syndrome. Curr Atheroscler Rep 2003; 5: 364-71.
18. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic volunteers. Diabetes Care 2000; 23: 171-5.
19. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
20. Murdolo G, Smith U. The dysregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis. Nutrition, Metabol Cardiovascul Dis 2006; 16: S35-S38.
21. Randle PJ, Garland PB, Hales CN , Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-9.
22. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664-71.
23. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-61.
24. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol 1999; 84: 21J-24J.
25. Caballero AE. Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation. Arch Med Res 2005; 36: 241-9.
26. Kuboki K, Jiang ZY, Takahara N, HA SW, Igarashi M, Yamauchi T, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000; 101: 676-81.
27. De Aguiar LG, Bahia LR, Villela N, Laflor C, Sicuro F, Wiernsperger N, et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006; 29: 1083-9.
28. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-10.
29. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
30. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, et al. Increased CD36 protein as a response to to defective insulin signalling in macrophages. J Clin Invest 2004; 113: 764-73.
31. Iida KT, Suzuki H, Sone H, Shimano H, Toyoshima H, Yatoh S, et al. Insulin inhibits apoptosis of macrophage cell line, THP-1 cells, via phosphatidylinositol-3-kinase-dependent pathway. Arterioscler Thromb Vasc Biol 2002; 22: 380-6.
32. Helderman JH. Acute regulation of human lymphocyte insulin receptors. Analysis by the glucose clamp. J Clin Invest 1984; 74; 1428-35.
33. Helderman JH, Pietri AO, Raskin P. In vitro control of T-lymphocyte insulin receptors by in vivo modulation of insulin. Diabetes 1983; 32: 712-7.